Click here to read the Cover story, “Targeted therapies shaping dry eye disease treatment”
There are two areas I am really excited about specifically in the areas of lid margin disease and dry eye disease.
No. 1 is the approval of Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) for the management of Demodex blepharitis. This lid margin disease is a very common comorbidity seen in almost 70% of dry eye disease (DED) patients that has a direct impact on the ocular surface.
Having medication has been incredible on multiple fronts. (Read more...)